of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

Sex: Female

Ages: 18 Years – 40 Years

Healthy volunteers: 1

Phase: PHASE3

Enrollment: 200

Sponsor: Beni-Suef University

Summary

The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and dapagliflozin as monotherapies and the effect of both of them as a combined therapy in infertile women with PCOs.

Eligibility Criteria

Inclusion Criteria:Women are aged between 18 and 45 yearsno pregnancy plan within the next 6 monthspolycystic ovarian syndrome (PCOS), according to Rotterdam criteriaExclusion Criteria:congenital adrenal hyperplasiapoorly controlled thyroid diseaseTaking antidiabetic drugs which can affect insulin resistancechronic kidney disease and history of recurrent urinary tract infectionsliver dysfunction (AST or ALT > 3 times the upper limit of normal or GFR<30 ml/min/1.73m2)documented use of oral hormonal contraceptives and hormone-releasing implants

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05601336). StuddyBuddy aggregates publicly available trial information.